Plant-based active ingredient shows success against asthma remodeling
A research team from Ruhr-Universität Bochum, the University of Bonn, Bonn University Hospital and Rutgers University (USA) has successfully tested an active ingredient from the coral berry Ardisia crenata against remodeling in bronchial asthma. The results were published in Molecular Therapy on July 23, 2025.

Bronchial asthma causes shortness of breath due to constricted airways, whereby anti-inflammatory medication often loses its effect and does not prevent the thickening of bronchial tissue due to collagen accumulation and increased mucus production by goblet cells. The active ingredient directly inhibits the Gq protein, reduces collagen deposition and mucus production. In a five-week mouse model in which the active substance was administered in liquid form into the lungs, remodeling decreased.
Tests on human cells and lung slices from deceased asthma patients also confirmed that the active ingredient slows down cell growth and reduces mucus secretion. It remains active for several days and also prevents the extreme contraction of the bronchial tubes, making it a promising candidate for future asthma therapies.
Original Paper:
Pharmacological Gq targeting prevents asthmatic airway remodeling – PubMed
Editorial office: X-Press Journalistenbüro GbR
Gender note. The personal designations used in this text always refer equally to female, male and diverse persons. Double/triple references and gendered designations are avoided for the sake of better readability ected.